654055-67-1

Upstream product

• 35903-52-7 fumagillol 
• 108-24-7 acetic anhydride 
• 135268-12-1 1-chloromethyl-3-methoxy-2-[2-methyl-3-(3-methylbut-2-enyl)oxiranyl]cyclohexane-1,4-diol 

Downstream Products

• 669064-72-6 Acetic acid (3R,4S,5S,6R)-4-{1-[(E)-benzyloxyimino]-ethyl}-5-methoxy-1-oxa-spiro[2.5]oct-6-yl ester 
• 654055-80-8 1-((3R,4S,5S,6R)-6-Hydroxy-5-methoxy-1-oxa-spiro[2.5]oct-4-yl)-ethanone O-benzyl-oxime 
• 654055-63-7 (E)-3-(3,4,5-Trimethoxy-phenyl)-acrylic acid (3R,4S,5S,6R)-4-((E)-1,5-dimethyl-hexa-1,4-dienyl)-5-methoxy-1-oxa-spiro[2.5]oct-6-yl ester 
• 654055-68-2 acetic acid 4-chloromethyl-3-(1,5-dimethylhexa-1,4-dienyl)-4-hydroxy-2-methoxycyclohexyl ester 

Relevant academic research and scientific papers

Investigation of novel fumagillin analogues as angiogenesis inhibitors

Modification of fumagillin was conducted to develop MetAP-2 inhibitors with desirable pharmacological properties. Replacement of the C4 side chain by benzyloxime preserves the inhibitory activity against MetAP-2 enzyme. Fumagillin analogues containing the

Design, synthesis and evaluation of a series of novel fumagillin analogues

A series of fumagillin analogues targeted at understanding tolerability of MetAP2 toward substitution at C4 and C6 were synthesized. Initially, the C6 side chain was maintained as cinnamoyl ester and C4 was modified. It was concluded that replacing the na